ArticleOncogene2001
p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis.
Article in Oncogene, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Key genes and drug delivery systems to improve the efficiency of chemotherapy.Cancer drug resistance (Alhambra, Calif.) · 2021Article
- Correlation of constitutive photomorphogenic 1 (COP1) and p27 tumor suppressor protein expression in ovarian cancer.Genes & genomics · 2019Article
- Article
- Hormonally up-regulated neu-associated kinase: A novel target for breast cancer progression.Pharmacological research · 2017Review
- SATB2 is localized to the centrosome and spindle maintenance and its knockdown leads to downregulation of CDK2.In vitro cellular & developmental biology. Animal · 2016Article
- COP1 enhances ubiquitin-mediated degradation of p27Kip1 to promote cancer cell growth.Oncotarget · 2015Article
- MicroRNA-mediated transformation by the Kaposi's sarcoma-associated herpesvirus Kaposin locus.Journal of virology · 2015Article
- Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis.Cell cycle (Georgetown, Tex.) · 2015Article
- Article
- CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity.Cell cycle (Georgetown, Tex.) · 2013Article
- CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6.Cell cycle (Georgetown, Tex.) · 2012Article
- IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance.The Journal of biological chemistry · 2011Article
- Hunk is required for HER2/neu-induced mammary tumorigenesis.The Journal of clinical investigation · 2011Article
- Effects of Ad-p27mt gene transfer on the expression of Bax, Bcl-2, VEGF and MMP-9 in the transplanted liver tumors in nude mice.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2010Article
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.Oncogene · 2007Review
- Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression.Cancer research · 2007Article
- Negative cell cycle regulator 14-3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt.Oncogene · 2006Article
- Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth.Cancer research · 2006Article
- The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells.Breast cancer research : BCR · 2006Article
- Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity.Oncogene · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
HER2/neu, a receptor tyrosine kinase oncogene, promotes mitogenic growth and transformation of cancer cells. We previously identified that its oncogenic signals down-regulate the cyclin-dependent kinase inhibitor p27 Kip1, which is defined as a haplo-insufficient tumor suppressor. Here, we applied the human p27 gene as a novel anticancer agent for HER2/neu-overexpressing cells under the control of a tetracycline (tet)-regulated gene expression system. Overexpression of p27 inhibits HER2/neu-activated CDK2 activity, cell proliferation, and transformation. Most significantly for clinical application, p27 expression in HER2/neu-overexpressing cells can be regulated in vivo and reduce the tumor volume in a tumor model. The findings demonstrate the applicability of employing p27 in HER2/neu-associated cancer gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.